Alere Determine Combo HIV 1/2 Ag/Ab rapid test for HIV
Alere Australia has gained approval for the marketing in Australia of the Alere Determine Combo HIV 1/2 Ag/Ab rapid test for HIV. This marks the first approval for an innovative HIV assay to be included on the Australian Register of Therapeutic Goods (ARTG) for use in a point-of-care situation.
Marketing approval required lengthy scrutiny by the TGA of the scientific and clinical evidence supporting the test, including its accuracy when performed in near patient situations by healthcare professionals other than pathology laboratory scientists.
The point-of-care test offers significant benefits to patients and to healthcare workers in terms of convenience and rapid management of immediate clinical issues. It brings HIV testing technology right to the patient’s bedside.
Phone: 07 3363 7100
ALA Scientific Instruments RuFus cell unroofing system for plasma membrane isolation
ALA Scientific Instruments offers RuFus, a complete and user-friendly system for performing cell...
Lonza plateable mouse hepatocytes
Lonza provides plateable mouse hepatocytes from the four most common research mouse strains,...
PEPperPRINT cLIFT peptide microarray platform
At the core of the technology is a laser-based transfer process that is designed to deposit amino...
